- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04122755
Single Ascending Dose Study of ALA-1000
A Single Ascending Dose, Open-Label Study Evaluating the Safety, Tolerability, And Pharmacokinetics of ALA-1000 in Opioid-Dependent Individuals
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will include opioid-dependent subjects who have been receiving stable, orally administered buprenorphine for at least 2 weeks or buprenorphine naïve subjects who will be stabilized on orally administered buprenorphine for 3 days prior to ALA-1000 administration.
All subjects will be washed off of oral buprenorphine for 7 days prior to ALA-1000 administration except Cohort 6 which will receive ALA-1000 administration after 7 days of buprenorphine sublingual film dosing.
The subsequent cohorts will be initiated after safety and PK information from the preceding cohorts is available.
The expected maximum duration of participation for each subject is 192 days approximately, consisting of up to a 7-day screening period, up to a 31-day residential phase, and up to a 154-day nonresidential period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33016
- Innovative Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Competent to provide informed consent.
- Voluntarily provide informed consent and Health Insurance Portability and Accounting Act (HIPAA) Authorization prior to any procedures or evaluations performed specifically for the sole purpose of the study.
- Male or female between 18 to 65 years of age inclusive at the screening visit.
- Meets DSM-5 criteria for Opioid Use Disorder (OUD) and is seeking treatment of OUD.
- Body Mass Index (BMI) ≥ 18 and ≤ 35 kg/m2 at screening visit.
- Female subjects of childbearing potential must agree to use a reliable method of birth control (e.g., total abstinence, condom and spermicide, intrauterine device (IUD), oral contraception which has been stable for 30 days) and at least 120 days after stopping the investigational product.
- Agree to withdraw from opiates for at least 12 hours prior to admission to clinical unit.
- Agree not to take any buprenorphine product (other than ALA-1000 and buprenorphine sublingual films during tolerability/induction period) during the study.
Exclusion Criteria:
- History or presence of a significant medical disease or disorder which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures, as confirmed by screening laboratory results.
- Clinically significant abnormal findings on physical examination, vital signs, or Electrocardiogram (ECG). Defined as having a QTc (Fridericia) interval > 470 msec or any other clinically significant abnormalities at screening, check-in, or prior to administration of ALA-1000.
- Pregnant or lactating.
- History of suicidal behavior in the past 1 year or current suicidal ideation as per investigator judgement.
- Currently meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for substance use disorder, moderate or severe for any substance other than opioids, caffeine, or nicotine.
- Currently meets criteria for any unstable psychiatric disorder, including schizophrenia, schizoaffective, bipolar disorder (depression and stable bipolar disorder are not excluded if condition has been stable for at least 60 days).
- Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS) as confirmed by Western Blot and viral load laboratory results.
- Acute active Hepatitis B or C as evidenced by positive serology and Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) >2 upper limit of normal (ULN)
- History of blood donation in excess of 450 mL within 30 days prior to Visit 1.
- Received treatment with an investigational drug or device within 90 days prior to Visit 1.
- Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 30 days prior to Visit 1.
- Use of any new medication, vitamins, or supplements within 7 days prior to Visit.
- Hypersensitivity or allergy to buprenorphine or other opioids which, in the opinion of the investigator, would compromise subject safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort1
Subjects receive a single subcutaneous injection of 1-fold ALA-1000 dose (first in human dose).
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
|
Experimental: Cohort2
Subjects receive a single subcutaneous injection of 2-fold ALA-1000 dose
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
|
Experimental: Cohort3
Subjects receive a single subcutaneous injection of 4.7-fold ALA-1000 dose
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
|
Experimental: Cohort4
Subjects receive a single subcutaneous injection of 9.4-fold ALA-1000 dose
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
|
Experimental: Cohort5
Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
|
Experimental: Cohort6
Subjects receive a single subcutaneous injection of 18.8-fold ALA-1000 dose after 7 days of buprenorphine sublingual film dosing
|
Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures.
Subjects remain in the residential phase through Day21 for safety assessment.
Other Names:
ALA-1000 injection after 7 days of buprenorphine sublingual film dosing.
Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of AEs will be summarized by treatment overall, by severity, and by relationship to ALA-1000. Serious AEs and AEs leading to discontinuation of study drug will also be presented.
Time Frame: Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
|
Change of vital signs will be assessed in subjects receiving ALA-1000.
Time Frame: Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Vital signs including blood pressure, pulse rate, respiration rate, pulse oximetry and temperature.
Systolic and diastolic blood pressure will be assessed while supine and standing.
Pulse oximetry will be monitored continuously for 24 hours post injection to assess for any signs/symptoms of respiratory depression.
|
Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Chang of clinical laboratory assessments (biochemistry, hematology and urinalysis) will be assessed in subjects receiving ALA-1000.
Time Frame: Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Samples will be collected for laboratory tests, including hematology, serum chemistry, urinalysis, serum/urine pregnancy test (conducted for females of childbearing potential only), and urine drug screen, to assess the safety of subjects.
|
Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Change of ECG parameter of QTcF interval will be assessed in subjects receiving ALA-1000
Time Frame: Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
|
A standard physical examination will be performed to monitor the safety in subjects receiving ALA-1000
Time Frame: Baseline (prior to dosing) to the End of Study (Day175), or Early termination
|
The examination will include assessment of skin, head, ears, eyes, nose, throat, neck, thyroid, lungs, heart, cardiovascular, abdomen, lymph nodes, and musculoskeletal system/extremities.
|
Baseline (prior to dosing) to the End of Study (Day175), or Early termination
|
Injection site assessment will be conducted to monitor the safety in subjects receiving ALA-1000
Time Frame: From the end of ALA-1000 injection through the End of Study (Day175), or Early termination
|
Injection site assessment including pain, tenderness, induration, erythema/redness, and swelling.
If an infection develops at the injection site, the subject will be withdrawn from the study.
|
From the end of ALA-1000 injection through the End of Study (Day175), or Early termination
|
Concomitant medications will be reviewed and documented to monitor the safety in subjects receiving ALA-1000
Time Frame: Prior to dosing through the End of Study (Day175), or Early termination
|
The medication name, dose, frequency, date, and indication for use must be recorded
|
Prior to dosing through the End of Study (Day175), or Early termination
|
AUC (area under the plasma concentration-time curve) for subjects receive ALA-1000 injection
Time Frame: Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
|
Cmax (maximum observed plasma concentration) for subjects receive ALA-1000 injection
Time Frame: Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
|
Tmax (time to maximum concentration) for subjects receive ALA-1000 injection
Time Frame: Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
|
t1/2 (time to half plasma concentration) for subjects receive ALA-1000 injection
Time Frame: Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
Prior to ALA-1000 injection through the End of Study (Day175), or Early termination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of opioid withdrawal symptoms will be assessed using Clinical Opiate Withdrawal Scale (COWS) for subjects receive ALA-1000 injection
Time Frame: Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Opioid withdrawal symptoms will be measured using COWS scores.
Score: 5- 1 2 = mild; 1 3-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal
|
Baseline (prior to dosing) through the End of Study (Day175), or Early termination
|
Change of suicidal ideation will be assessed using Columbia-Suicide Severity Rating Scale (C-SSRS) for subjects receive ALA-1000 injection
Time Frame: Screening through the End of Study (Day175), or Early termination
|
Suicidal ideation scores will be reported using C-SSRS.
The suicidal ideation scale identifies behaviors and thoughts that are associated with an increased risk of suicidal actions in the future.
Score: 5- 1 2 = mild; 1 3-24 = moderate; 25-36 = moderately severe; more than 36 = severe suicidal ideation.
|
Screening through the End of Study (Day175), or Early termination
|
Assessment of the abstinence by urine toxicology results negative for opioids in subjects received ALA-1000 injection.
Time Frame: Screening through the End of Study (Day175), or Early termination
|
Screening through the End of Study (Day175), or Early termination
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Erin Tireman, Innovative Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Buprenorphine
Other Study ID Numbers
- A1-19-P01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)RecruitingOpioid Use Disorder | Opioid Use | Cocaine Use Disorder | Cocaine UseUnited States
Clinical Trials on ALA-1000
-
National Institute of Diabetes and Digestive and...CompletedDiabetes Mellitus, Insulin-DependentUnited States
-
National Center for Research Resources (NCRR)Juvenile Diabetes Research FoundationUnknownIslets of Langerhans Transplantation | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Experimental | Transplantation, HomologousUnited States
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Terminated
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile...Completed
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
Biofrontera Bioscience GmbHCompleted
-
Invion, Inc.Completed
-
University of TorontoInstitut National de la Santé Et de la Recherche Médicale, France; University...Unknown
-
Assuta Hospital SystemsUnknownBasal Cell CarcinomaIsrael